NET ASSET VALUE – 31 March 2025

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

NET ASSET VALUE – 31 March 2025

MARKN.

On the 31 March 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,947 million and NAV per share was SEK 50.56.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development
Prokarium	42%	456	5.84	11.6%
Empros Pharma	79%	204	2.62	5.2%
Xspray Pharma	18%	192	2.46	4.9%
KAHR Medical	31%	189	2.43	4.8%
Atrogi	37%	176	2.25	4.4%
Lipum	57%	170	2.17	4.3%
Xintela	61%	162	2.08	4.1%
Microbiotica	10%	130	1.66	3.3%
Geneos Therapeutics	12%	96	1.23	2.4%
Toleranzia	66%	79	1.01	2.0%
Mendus	24%	74	0.94	1.9%
AnaCardio	14%	69	0.89	1.8%
EpiEndo Pharmaceuticals	9%	54	0.69	1.4%
Synerkine Pharma	43%	54	0.69	1.4%
Vitara Biomedical	11%	50	0.64	1.3%
Buzzard Pharmaceuticals	14%	29	0.37	0.7%
Sixera Pharma	24%	27	0.35	0.7%
Egetis Therapeutics	2%	23	0.29	0.6%
Alder Therapeutics	21%	17	0.22	0.4%
Amarna Therapeutics	58%	11	0.14	0.3%
Strike Pharma	16%	9	0.11	0.2%
Total		2,270	29.08	57.5%

Commercial Growth
NorthX Biologics	92%	189	2.42	4.8%
Symcel	31%	174	2.23	4.4%
Chromafora	31%	73	0.93	1.8%
Nanologica	43%	48	0.61	1.2%
Frontier Biosolutions	2%	18	0.23	0.5%
Bohus Biotech	45%	17	0.21	0.4%
Provell Pharmaceuticals*	72%	0	0.00	0.0%
Total		518	6.64	13.1%

Limited Partnerships, total		85	1.09	2.2%

Assets related to Portfolio companies		262	3.35	6.6%
Other assets and liabilities		811	10.39	20.6%

Net asset value		3,947	50.56	100.0%

* indirect shares in Provell Pharmaceuticals

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Datum	2025-04-03, kl 08:00
Källa	MFN

Bifogade filer

NET ASSET VALUE – 31 March 2025

LOGGA IN

Flerie

Affiliate

NET ASSET VALUE – 31 March 2025